Friday, August 14, 2026

Creating liberating content

Bitcoin’s stall around $63,000...

The S&P 500 closed Thursday at a record 7,798.99, while Bitcoin traded at...

Data Breach At Trezor...

Hardware wallet manufacturer Trezor has announced a data breach exposing customer...

Multicoin exits the $1.65...

Multicoin Capital has exited its disclosed stake in Forward Industries, the largest Solana...

UBS Ups Bitcoin Position,...

Switzerland’s largest bank has upped its exposure to Bitcoin, according...

Bakkt Q2 2026 Results: $80.8M Profit Explained

Bakkt, a digital-asset infrastructure company, reported $80.8 million of net income attributable to the company in its Q2 2026 results, reversing a $14.7 million loss a year earlier. But its Aug. 10 results show that investment marks, rather than an improvement in crypto-services operations, drove the profit.

Related Reading

Bakkt promised a $44 trillion payment revolution, but its key acquisition made just €5,315

The 2025 statements recorded €5,315 in other income and €373,857 in cash before the April acquisition.

Aug 10, 2026 · Liam ‘Akiba’ Wright

The largest item was a $98.5 million non-cash gain from revaluing warrants in Transchem, an Indian listed company. A separate legacy warrant liability added another $1.4 million non-cash gain. Removing both marks from Bakkt’s $81.1 million pre-tax result before the equity-method loss produces an illustrative pre-tax loss of about $18.8 million. That is not a company-reported GAAP or non-GAAP subtotal, but it shows how strongly the headline result depended on fair-value accounting.

Read More:  Robinhood’s crypto revenue plunged 38%, but a sudden explosion in options trading saved its record quarter

The Transchem gain reflects a recognized but unrealized increase in the fair value of a warrant asset that will be remeasured through earnings each period. A June 4 SEC filing shows that Bakkt paid $9.4 million, equal to 25% of the subscription price, for 47.5 million Transchem warrants after they were allotted in June.

The position was carried at $107.9 million on June 30, and Bakkt would owe about $28.2 million more if it fully exercises the warrants within 18 months. Bakkt cautioned that its aggregate Strategic Asset Value, which includes the Transchem position, does not represent market or liquidation value.